AB Science

AB Science reports that its drug AB8939, combined with venetoclax, produced a 100% partial response rate in four hard-to-treat AML patients (1 complete remission, 1 near-complete remission, 2 partial responses). The treatment was well tolerated with no hematologic or dose‑limiting toxicity. The company plans to complete the phase 1, start an expansion study with about 15 patients, and is in discussions with regulators; AB8939 has orphan drug status in the EU and USA. InvestingPro notes a market capitalization of USD 3.57 billion and classifies AB Science as undervalued in its proprietary fair‑value model. » Plus sur de.investing.com

AB Science reports that the combination of AB8939 plus Venetoclax produced a 100% partial response rate in a phase‑1 study of three patients with refractory or relapsed acute myeloid leukemia, including a complete remission after the first 14‑day cycle. The combination appeared to be well tolerated with limited hematologic toxicity. The company plans an expansion study of around 15 patients, is evaluating designs for registrational trials, and estimates an addressable market of more than €2 billion per year. » Plus sur de.investing.com

AB Science reports that in an ongoing phase‑1 study the first three patients with refractory/relapsed acute myeloid leukemia treated with AB8939 in combination with Venetoclax achieved a 100% partial response rate after 14 days; one patient reached complete remission. Two of the patients had previously progressed on Venetoclax‑based combinations. The combination was well tolerated with no reported hematologic toxicity; the program will now proceed with dose escalation followed by an expansion phase of about 15 patients. AB8939 has orphan drug status in the EU and US; the company plans a virtual expert meeting and expects further data on October 23, after analysts have already raised their estimates. » Plus sur de.investing.com